The Swiss Light Source (SLS) at the Paul Scherrer Institut is a third-generation synchrotron light source. In the design of SLS a high priority was given to the items quality (high brightness), flexibility (wide wavelength spectrum) and stability (very stable temperature conditions) for the primary electron beam and the secondary photon beams.
With an energy of 2.4 GeV, it provides photon beams of high brightness for research in materials science, biology and chemistry.
The experimental program started in June 2001. As of June 2009 SLS has eighteen experimental stations (undulators and bending magnets) and seventeen operational beamlines. There are three protein crystallography beam-lines, two of which are partially funded by associations of Swiss pharmaceutical companies including Novartis, Roche, Actelion, Boehringer Ingelheim and Proteros.
Some special features of SLS are:
Deadlines for PX beamlines:
Deadlines for non-PX beamlines: